Associated British Foods PLC (LON:ABF) Investors: Shore Capital Keeps Buy Rating, Sees GBX 2583.00/Share; Ocular Therapeutix, Inc. (OCUL) Had 7 Bulls

Associated British Foods plc (LON:ABF) Logo

In a note issued to clients on 17 April, Associated British Foods PLC (LON:ABF) stock Buy was reaffirmed at Shore Capital. They currently have a GBX 2583.00 target price on the stock. Shore Capital’s target price indicates a potential downside of -2.51% from the company’s previous close.

Among 8 analysts covering Ocular Therapeutix (NASDAQ:OCUL), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Ocular Therapeutix had 25 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Equal-Weight” rating by Morgan Stanley given on Friday, June 23. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, August 9 report. Morgan Stanley maintained it with “Overweight” rating and $16 target in Tuesday, June 7 report. Guggenheim initiated the shares of OCUL in report on Monday, October 23 with “Buy” rating. The company was maintained on Thursday, March 8 by Cantor Fitzgerald. The rating was maintained by Cantor Fitzgerald with “Buy” on Monday, July 10. The rating was maintained by BTIG Research on Thursday, March 8 with “Buy”. H.C. Wainwright maintained the shares of OCUL in report on Friday, March 9 with “Buy” rating. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, August 2. The company was initiated on Thursday, August 13 by Morgan Stanley. See Ocular Therapeutix, Inc. (NASDAQ:OCUL) latest ratings:

08/03/2018 Broker: BTIG Research Rating: Buy New Target: $9.0 Maintain
09/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $10.0 Maintain
08/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $22.0 Maintain
19/01/2018 Broker: BTIG Research Old Rating: Neutral New Rating: Buy Upgrade
08/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $10.0 Maintain
07/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $21.0 Maintain
23/10/2017 Broker: Guggenheim Rating: Buy New Target: $12.0 Initiate

The stock decreased 1.39% or $0.09 during the last trading session, reaching $6.39. About 154,386 shares traded. Ocular Therapeutix, Inc. (NASDAQ:OCUL) has declined 32.37% since April 17, 2017 and is downtrending. It has underperformed by 43.92% the S&P500.

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of ocular therapies using its Hydrogel technology. The company has market cap of $238.21 million. The Company’s product pipeline candidates utilize its platform to provide differentiated drug delivery solutions that are designed to reduce the complexity and burden of current drop or injection regimens by creating sustained release one-time or several-month dosage forms. It currently has negative earnings. The companyÂ’s lead product candidate, DEXTENZA 0.4 mg for intracanalicular use has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.

The stock increased 2.67% or GBX 69 during the last trading session, reaching GBX 2652. About 492,502 shares traded. Associated British Foods plc (LON:ABF) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Ratings Chart